Only specific p53 mutations, determined by sequencing of the p53 gene, are most informative in predicting response to systemic therapy of advanced breast cancer (Berns et al, 2000), whereas we examined early stage breast cancer by p53 immunohistochemistry, which is less accurate in detecting mutations. The gene discussed is TP53; the disease is breast carcinoma.